Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novel Virus Brings Novel Threats To Global Pharmaceutical Manufacturing

Executive Summary

As coronavirus spreads into China’s manufacturing region, quarantines and travel restrictions challenge international flow of pharmaceuticals, ingredients and personnel.

You may also be interested in...



BARDA Begins Stockpiling APIs For Critical Drugs

US agency ensures pharmaceutical companies could manufacture critical medicines domestically even if cut off from China's API suppliers, while stockpiling pandemic medicines during pandemic with Baxter, Fresenius contracts.

Drug Shortage Legislation Gains Support As Coronavirus Threatens US Supplies

Coronavirus hysteria sweeps up languishing drug shortage legislation; prospects for new reporting and risk management planning requirements improve.

A Rebuke To Pharma Globalization? Coronavirus Shows Value Of Regional Supply Chain Redundancy

As virus impedes China’s API production and spreads to other global manufacturing centers, need for robust supply chain alternatives becomes clear.

Related Content

Topics

UsernamePublicRestriction

Register

PS141614

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel